A phase II trial of FUdR in patients with advanced pancreatic cancer

Bach Ardalan, Mayra Lima

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: This phase II study was conducted to assess the efficacy of fluorodeoxyuridine (FUdR) in patients with metastatic, advanced pancreatic cancer who had no previous chemotherapy. Patients and methods: Twenty patients were enrolled in this single institution trial. The primary endpoint of this study was the assessment of overall survivorship. The secondary endpoints were to estimate the time to tumor progression and the assessment of toxicity in this cohort of patients. Treatment consisted of FUdR 150 mg/kg dissolved in 500 cc normal saline intravenous infusion over 24 h. Eight weeks of treatment constituted one course of chemotherapy. Tumor measurements were conducted at 8-weekly intervals. Results: Four patients achieved partial response and 16 patients had stable disease. Median survival of patients treated with FUdR was 11.6 months with a range of 3-16 months. Median progression-free survival was 6 months. Overall, chemotherapy was well tolerated with low incidence of grade 3 or 4 toxicity. Conclusions: Systemic chemotherapy with high dose FUdR administered on a weekly schedule has led to encouraging survival outcomes and improved quality of life as compared to previous phase II single agent chemotherapeutic trials.

Original languageEnglish
Pages (from-to)561-566
Number of pages6
JournalJournal of Cancer Research and Clinical Oncology
Volume130
Issue number10
DOIs
StatePublished - Oct 1 2004

Fingerprint

Floxuridine
Pancreatic Neoplasms
Drug Therapy
Survival
Intravenous Infusions
Disease-Free Survival
Neoplasms
Appointments and Schedules
Survival Rate
Quality of Life
Incidence
Therapeutics

Keywords

  • Chemotherapy
  • FUdR (Floxuridine)
  • Survival
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II trial of FUdR in patients with advanced pancreatic cancer. / Ardalan, Bach; Lima, Mayra.

In: Journal of Cancer Research and Clinical Oncology, Vol. 130, No. 10, 01.10.2004, p. 561-566.

Research output: Contribution to journalArticle

@article{18f4373e95b4441899ccfcf3fa1f59f1,
title = "A phase II trial of FUdR in patients with advanced pancreatic cancer",
abstract = "Purpose: This phase II study was conducted to assess the efficacy of fluorodeoxyuridine (FUdR) in patients with metastatic, advanced pancreatic cancer who had no previous chemotherapy. Patients and methods: Twenty patients were enrolled in this single institution trial. The primary endpoint of this study was the assessment of overall survivorship. The secondary endpoints were to estimate the time to tumor progression and the assessment of toxicity in this cohort of patients. Treatment consisted of FUdR 150 mg/kg dissolved in 500 cc normal saline intravenous infusion over 24 h. Eight weeks of treatment constituted one course of chemotherapy. Tumor measurements were conducted at 8-weekly intervals. Results: Four patients achieved partial response and 16 patients had stable disease. Median survival of patients treated with FUdR was 11.6 months with a range of 3-16 months. Median progression-free survival was 6 months. Overall, chemotherapy was well tolerated with low incidence of grade 3 or 4 toxicity. Conclusions: Systemic chemotherapy with high dose FUdR administered on a weekly schedule has led to encouraging survival outcomes and improved quality of life as compared to previous phase II single agent chemotherapeutic trials.",
keywords = "Chemotherapy, FUdR (Floxuridine), Survival, Toxicity",
author = "Bach Ardalan and Mayra Lima",
year = "2004",
month = "10",
day = "1",
doi = "10.1007/s00432-004-0584-5",
language = "English",
volume = "130",
pages = "561--566",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - A phase II trial of FUdR in patients with advanced pancreatic cancer

AU - Ardalan, Bach

AU - Lima, Mayra

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Purpose: This phase II study was conducted to assess the efficacy of fluorodeoxyuridine (FUdR) in patients with metastatic, advanced pancreatic cancer who had no previous chemotherapy. Patients and methods: Twenty patients were enrolled in this single institution trial. The primary endpoint of this study was the assessment of overall survivorship. The secondary endpoints were to estimate the time to tumor progression and the assessment of toxicity in this cohort of patients. Treatment consisted of FUdR 150 mg/kg dissolved in 500 cc normal saline intravenous infusion over 24 h. Eight weeks of treatment constituted one course of chemotherapy. Tumor measurements were conducted at 8-weekly intervals. Results: Four patients achieved partial response and 16 patients had stable disease. Median survival of patients treated with FUdR was 11.6 months with a range of 3-16 months. Median progression-free survival was 6 months. Overall, chemotherapy was well tolerated with low incidence of grade 3 or 4 toxicity. Conclusions: Systemic chemotherapy with high dose FUdR administered on a weekly schedule has led to encouraging survival outcomes and improved quality of life as compared to previous phase II single agent chemotherapeutic trials.

AB - Purpose: This phase II study was conducted to assess the efficacy of fluorodeoxyuridine (FUdR) in patients with metastatic, advanced pancreatic cancer who had no previous chemotherapy. Patients and methods: Twenty patients were enrolled in this single institution trial. The primary endpoint of this study was the assessment of overall survivorship. The secondary endpoints were to estimate the time to tumor progression and the assessment of toxicity in this cohort of patients. Treatment consisted of FUdR 150 mg/kg dissolved in 500 cc normal saline intravenous infusion over 24 h. Eight weeks of treatment constituted one course of chemotherapy. Tumor measurements were conducted at 8-weekly intervals. Results: Four patients achieved partial response and 16 patients had stable disease. Median survival of patients treated with FUdR was 11.6 months with a range of 3-16 months. Median progression-free survival was 6 months. Overall, chemotherapy was well tolerated with low incidence of grade 3 or 4 toxicity. Conclusions: Systemic chemotherapy with high dose FUdR administered on a weekly schedule has led to encouraging survival outcomes and improved quality of life as compared to previous phase II single agent chemotherapeutic trials.

KW - Chemotherapy

KW - FUdR (Floxuridine)

KW - Survival

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=5644258598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644258598&partnerID=8YFLogxK

U2 - 10.1007/s00432-004-0584-5

DO - 10.1007/s00432-004-0584-5

M3 - Article

C2 - 15449185

AN - SCOPUS:5644258598

VL - 130

SP - 561

EP - 566

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 10

ER -